Pfizer and YaoPharma Forge $2.1B Alliance to Advance Oral GLP-1 Drug
Pfizer has forged an exclusive global partnership with YaoPharma to develop and commercialize YP05002, a small-molecule GLP-1 agonist for chronic weight management.
Pfizer
Pfizer wins $10 billion bidding war for Metsera after competitive bidding with Novo Nordisk
Months of legal challenges, court rulings, and regulatory probes define the industry’s fiercest metabolic takeover fight Pfizer has signed a definitive agreement to acquire metabolic biotech Metsera, ending months of one of the most aggressive takeover battles in recent biopharma history. The deal concludes a dramatic contest with Novo Nordisk, which had initially secured Metsera’s … Read more
Takeover Battle: Novo Nordisk Wins Brave Court Victory in $10B Metsera Deal Amid FTC Probe
Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.
Metsera responds to Pfizer lawsuit, defends board process in Novo bid dispute
Pfizer’s GLP-1 lawsuit tests biosimilar ambitions and contract guardrails.
Novo’s unsolicited bid for Metsera challenges Pfizer pact
Novo’s unsolicited Metsera bid could upend Pfizer pact and reshape the GLP-1 race.
Pfizer picks Triana Biomedicines to find Molecular Glues for Cancer
US pharmaceutical giant Pfizer announced a groundbreaking collaboration with Triana Biomedicines to develop Molecular Glue Degraders. The partnership aims to create multiple advanced therapies, including cancer. The collaboration is seen as a significant step forward in developing advanced medical treatments that can address challenging disease targets. Targeted protein degradation is a novel and fast-growing segment. … Read more